Saturday, July 11, 2026

Drug profile · INN

conestat alfa

conestat alfa (RUCONEST) is a plasma protease c1 inhibitor exogenous protein.

EMA: approved Blood and blood forming organs (B06) B06AC04
Patents linked 0
Pipeline programs 0
News articles 0
Drug details — conestat alfa
Class
Blood and blood forming organs (B06)
Route
Patents
0
Programs
0
Data quality
0.83

Quick answer

conestat alfa (RUCONEST) is a plasma protease c1 inhibitor exogenous protein.

Key facts

INN conestat alfa
Brand RUCONEST
Mechanism Plasma protease C1 inhibitor exogenous protein
Target Plasma protease C1 inhibitor
Therapeutic class Blood and blood forming organs (B06)
ATC code B06AC04

Mechanism of action

Plasma protease C1 inhibitor exogenous protein

Primary target: Plasma protease C1 inhibitor

Approval history

Authority Status Date
EMA approved

Related & competitor drugs

  1. apixaban Blood and blood forming organs (B01)
  2. berotralstat Blood and blood forming organs (B06)
  3. bivalirudin Blood and blood forming organs (B01)
  4. c1 inhibitor (human) Blood and blood forming organs (B06)
  5. clopidogrel Blood and blood forming organs (B01)
  6. dabigatran etexilate Blood and blood forming organs (B01)

Frequently asked questions

What is conestat alfa?

conestat alfa (RUCONEST) is a plasma protease c1 inhibitor exogenous protein.

What is the brand name for conestat alfa?

RUCONEST is a marketed brand name for conestat alfa. Check FDA Drugs@FDA for the current US label holder and prescribing information.